Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
The FDA has granted Fast Track designation for elritercept for very low-, low- and intermediate-risk MDS.On Tuesday, Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.
星期二，武田製藥股份有限公司（紐交所：TAK）與keros therapeutics公司（納斯達克：KROS）簽署了一項獨家許可協議，以進一步開發、製造和全球商業化elritercept，在中國大陸、香港和澳門之外的世界範圍內。
Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis.
Elritercept是一種已進入晚期研究的activin抑制劑，旨在治療與某些血液學癌症相關的貧血，包括骨髓增生異常綜合症和骨髓纖維化。
Also Read: Analyst Sees Keros Therapeutics As Next Acceleron, the Set For Major Biotech Growth
分析師認爲Keros Therapeutics是下一個Acceleron，爲主要生物技術增長做準備
The FDA has granted Fast Track designation for elritercept for very low-, low- and intermediate-risk MDS.
FDA已授予elritercept用於治療非常低風險、低風險和中等風險骨髓增生異常的快速通道認定。
Myelodysplastic syndromes and myelofibrosis are characterized by inadequate blood cell production, often leading to severe anemia.
骨髓增生異常綜合症和骨髓纖維化的特點是血細胞生產不足，常常導致嚴重貧血。
Elritercept targets activin A and B proteins, which are believed to be crucial in anemia-associated diseases.
Elritercept作用靶點是activin A和b蛋白，據信在與貧血相關的疾病中至關重要。
In early clinical studies, elritercept has shown promising clinical activity and a manageable safety profile in patients with very low-, low- and intermediate-risk myelodysplastic syndromes as a monotherapy and in patients with myelofibrosis in combination with standard of care.
在早期臨床研究中，elritercept在非常低風險、低風險和中等風險骨髓增生異常患者中作爲單藥療法以及在與標準治療聯合應用下治療骨髓纖維化患者方面顯示出有希望的臨床活性和可管理的安全性。
Elritercept is currently in two ongoing Phase 2 trials for very low-, low- or intermediate-risk myelodysplastic syndromes and myelofibrosis patients.
Elritercept目前正在進行兩項針對非常低、低或中度骨髓增生異常和骨髓纖維化患者的進行中2期臨床試驗。
The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk myelodysplastic syndromes will begin enrollment soon.
RENEW試驗的第3階段將很快開始招募，評估elritercept在成年患有輸血依賴性貧血的患者中的應用，這些患者患有非常低、低或中等風險的骨髓增殖異常綜合徵。
Takeda plans to evaluate elritercept in these cancers across patient segments and lines of therapy.
武田計劃在患者細分群和治療線中評估elritercept在這些癌症中的應用。
Takeda will pay Keros Therapeutics an upfront payment of $200 million and is eligible to receive milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.
武田將向Keros Therapeutics支付20000萬美元的預付款，並有資格獲得超過11億美元的里程碑。Keros還有資格根據淨銷售額獲得分階段的版稅。
William Blair writes that With Takeda taking responsibility for elritercept development, Keros (Outperform rating) will now have two wholly owned assets, including cibotercept in pulmonary arterial hypertension and KER-065 in obesity and neuromuscular indications, allowing Keros to narrow its focus.
William Blair指出，隨着武田負責elritercept的開發，Keros（表現優異評級）現在將擁有兩個全部擁有的資產，包括治療肺動脈高壓的cibotercept和治療肥胖症和神經肌肉疾病的KER-065，這使Keros能夠專注於其核心業務。
The analyst notes that multiple offers for elritercept were received. Management believes that Takeda is aligned with its views on the broader opportunity for elritercept.
分析師指出，收到了多個有關elritercept的要約。管理層認爲武田與其在elritercept的廣闊機會上的觀點一致。
